PMID- 34694649
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220731
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Print)
IS  - 0278-0232 (Linking)
VI  - 40
IP  - 1
DP  - 2022 Feb
TI  - Brentuximab vedotin consolidation after autologous stem cell transplantation for 
      Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
PG  - 31-39
LID - 10.1002/hon.2939 [doi]
AB  - The standard management for relapsed or refractory classical Hodgkin lymphoma 
      (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). 
      This strategy allows almost 50% of patients to be cured. Post-ASCT maintenance 
      treatment with brentuximab vedotin (BV) confers improved progression-free 
      survival (PFS) to cHL patients at high risk of relapse. We investigated the 
      outcome of 105 cHL patients receiving post-ASCT BV maintenance in the real-life 
      setting of 23 Italian hematology centers. This population included naive patients 
      and those previously exposed to BV. Median follow-up was 20 months. Patients 
      presented a median of two lines of treatment pre-ASCT, with 51% receiving BV. 
      Twenty-nine percent of patients had at least two high-risk factors (refractory 
      disease, complete response [CR] less than 12 months, extranodal disease at 
      relapse), while 16% presented none. At PET-CT, a Deauville score (DS) of 1-3 was 
      reported in 75% and 78% of pre- and post-ASCT evaluations, respectively. Grade 
      3-4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of 
      patients. Three-year PFS and overall survival (OS) were 62% and 86%, 
      respectively. According to BV exposure, 3-year PFS and OS were 54% and 71%, 
      respectively, for naive and 77% and 96%, respectively, for previously exposed 
      patients. Refractory disease (hazard ratio [HR] 4.46; p = 0.003) and post-ASCT DS 
      4-5 (HR 3.14; p = 0.005) were the only two factors significantly associated with 
      PFS reduction in multivariable analysis. Post-ASCT BV maintenance is an 
      effective, safe treatment option for cHL naive patients and those previously 
      exposed to BV.
CI  - (c) 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
FAU - Massaro, Fulvio
AU  - Massaro F
AUID- ORCID: 0000-0002-8448-7957
AD  - PhD Program in Clinical and Experimental Medicine, University of Modena and 
      Reggio Emilia, Modena, Italy.
AD  - Hematology Unit, Azienda Unita Sanitaria Locale-IRCCS di Reggio Emilia, Reggio 
      Emilia, Italy.
FAU - Pavone, Vincenzo
AU  - Pavone V
AD  - Department of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, 
      Tricase, Italy.
FAU - Stefani, Piero Maria
AU  - Stefani PM
AD  - Hematology Unit, General Hospital Ca' Foncello, Treviso, Italy.
FAU - Botto, Barbara
AU  - Botto B
AD  - Division of Hematology, Citta della Salute e della Scienza Hospital and 
      University, Torino, Italy.
FAU - Pulsoni, Alessandro
AU  - Pulsoni A
AD  - Department of Translational and Precision Medicine, Sapienza University, Rome, 
      Italy.
FAU - Patti, Caterina
AU  - Patti C
AD  - Division of Onco-Hematology, Azienda Villa Sofia-Cervello, Palermo, Italy.
FAU - Cantonetti, Maria
AU  - Cantonetti M
AD  - Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata, Rome, Italy.
FAU - Visentin, Andrea
AU  - Visentin A
AUID- ORCID: 0000-0003-0271-7200
AD  - Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), 
      University of Padua, Padua, Italy.
FAU - Scalzulli, Potito Rosario
AU  - Scalzulli PR
AD  - Department of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, 
      Italy.
FAU - Rossi, Andrea
AU  - Rossi A
AD  - Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, 
      Italy.
FAU - Galimberti, Sara
AU  - Galimberti S
AD  - Division of Hematology, Department of Clinical and Experimental Medicine, 
      University of Pisa, Italy.
FAU - Cimminiello, Michele
AU  - Cimminiello M
AD  - Hematology, San Carlo Hospital, Potenza, Italy.
FAU - Gini, Guido
AU  - Gini G
AD  - Division of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, 
      Ancona, Italy.
FAU - Musso, Maurizio
AU  - Musso M
AD  - Department of Oncology, Hematology and BMT Unit, Casa di Cura La Maddalena, 
      Palermo, Italy.
FAU - Sorio, Marco
AU  - Sorio M
AD  - Department of Clinical and Experimental Medicine, Hematology and Bone Marrow 
      Transplant Unit, University of Verona, Verona, Italy.
FAU - Arcari, Annalisa
AU  - Arcari A
AD  - Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
FAU - Zilioli, Vittorio Ruggero
AU  - Zilioli VR
AD  - Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, 
      Italy.
FAU - Luppi, Mario
AU  - Luppi M
AD  - Department of Medical and Surgical Sciences, University of Modena and Reggio 
      Emilia, Modena, Italy.
FAU - Mannina, Donato
AU  - Mannina D
AD  - Unit of Haematology, Azienda Ospedaliera Papardo, Messina, Italy.
FAU - Fabbri, Alberto
AU  - Fabbri A
AD  - Hematology, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
FAU - Pietrantuono, Giuseppe
AU  - Pietrantuono G
AD  - Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento 
      Oncologico della Basilicata, Rionero in Vulture, Italy.
FAU - Annibali, Ombretta
AU  - Annibali O
AUID- ORCID: 0000-0002-3095-5313
AD  - Unit of Haematology and Stem Cell Transplantation, Campus Bio-Medico University, 
      Rome, Italy.
FAU - Tafuri, Agostino
AU  - Tafuri A
AD  - Department of Clinical and Molecular Medicine and Hematology, Sant'Andrea - 
      University Hospital - Sapienza, University of Rome, Rome, Italy.
FAU - Prete, Eleonora
AU  - Prete E
AD  - Department of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, 
      Tricase, Italy.
FAU - Mule, Antonino
AU  - Mule A
AD  - Division of Onco-Hematology, Azienda Villa Sofia-Cervello, Palermo, Italy.
FAU - Barbolini, Elisa
AU  - Barbolini E
AD  - Gruppo Amici dell'Ematologia GRADE-Onlus Foundation, Reggio Emilia, Italy.
FAU - Marcheselli, Luigi
AU  - Marcheselli L
AD  - Fondazione Italiana Linfomi Onlus, Modena, Italy.
FAU - Luminari, Stefano
AU  - Luminari S
AD  - Hematology Unit, Azienda Unita Sanitaria Locale-IRCCS di Reggio Emilia, Reggio 
      Emilia, Italy.
FAU - Merli, Francesco
AU  - Merli F
AD  - Hematology Unit, Azienda Unita Sanitaria Locale-IRCCS di Reggio Emilia, Reggio 
      Emilia, Italy.
LA  - eng
GR  - Takeda/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211101
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 7XL5ISS668 (Brentuximab Vedotin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Brentuximab Vedotin/*therapeutic use
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hematopoietic Stem Cell Transplantation/*mortality
MH  - Hodgkin Disease/*drug therapy/pathology/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Young Adult
PMC - PMC9298220
OTO - NOTNLM
OT  - AETHERA trial
OT  - autologous stem cell transplantation
OT  - brentuximab vedotin
OT  - hodgkin lymphoma
COIS- A. Pulsoni, M. Cantonetti, A. Rossi, V.R. Zilioli, A. Fabbri, F. Merli have a 
      consultant or advisory role for Takeda; M. Cantonetti, A. Visentin, A. Fabbri 
      received educational grant from Takeda.
EDAT- 2021/10/26 06:00
MHDA- 2022/02/15 06:00
PMCR- 2022/07/20
CRDT- 2021/10/25 12:34
PHST- 2021/10/17 00:00 [revised]
PHST- 2021/08/31 00:00 [received]
PHST- 2021/10/18 00:00 [accepted]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
PHST- 2021/10/25 12:34 [entrez]
PHST- 2022/07/20 00:00 [pmc-release]
AID - HON2939 [pii]
AID - 10.1002/hon.2939 [doi]
PST - ppublish
SO  - Hematol Oncol. 2022 Feb;40(1):31-39. doi: 10.1002/hon.2939. Epub 2021 Nov 1.